The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...

Experts discuss why it is critical to have standardized protocols in place for managing cytokine release syndrome (CRS) in patients receiving bispecific antibodies, outlining the key components of an ...

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment nearing completion.

Results showed the agent lessened severity of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome (ICANS) for a majority of treated patients. “We expected to see ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug ...